Back to today’s briefing

Story perspectives

Pfizer, Summit Collaborate on Promising Cancer Drug Trials

2/24/2025

41 4

Summary

Story summary

Pfizer and Summit Therapeutics are joining forces to launch clinical trials in mid-2025, testing Summit's promising ivonescimab alongside Pfizer's antibody-drug conjugates for solid tumors. While both companies will maintain product rights, Summit's stock experienced volatility after the announcement, despite encouraging Phase III trial results showing ivonescimab's potential against Keytruda in advanced lung cancer.

1 of 1

Story summary

Pfizer and Summit Therapeutics are joining forces to launch clinical trials in mid-2025, testing Summit's promising ivonescimab alongside Pfizer's antibody-drug conjugates for solid tumors. While both companies will maintain product rights, Summit's stock experienced volatility after the announcement, despite encouraging Phase III trial results showing ivonescimab's potential against Keytruda in advanced lung cancer.